SEHK:3692Pharmaceuticals
A Look At Hansoh Pharmaceutical Group’s Valuation As XINYUE Gains Third Rare Disease Approval In China
Hansoh Pharmaceutical Group (SEHK:3692) has secured NMPA approval for XINYUE’s third indication, targeting adult patients with generalized myasthenia gravis, and expanding its rare autoimmune disease footprint supported by positive Phase III MINT trial data.
See our latest analysis for Hansoh Pharmaceutical Group.
The XINYUE approval lands at a time when the share price has climbed to HK$39.4, with a 30 day share price return of 21.6% and a 1 year total shareholder return of 82.34%. This...